[Universal newborn hearing screening in Cantabria (Spain): results of the first two years].
| Autor: | González de Aledo Linos A; Sección de Promoción y Educación para la Salud, Gobierno de Cantabria, Cantabria, Spain. gonzalezdealedo_a@gobcantabria.es, Bonilla Miera C, Morales Angulo C, Gómez Da Casa F, Barrasa Benito J |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Anales de pediatria (Barcelona, Spain : 2003) [An Pediatr (Barc)] 2005 Feb; Vol. 62 (2), pp. 135-40. |
| DOI: | 10.1157/13071310 |
| Abstrakt: | Aims: We present the results of the first 2 years of universal newborn hearing screening in Cantabria. Material and Methods: We performed a descriptive study of screening with two levels of transient evoked otoacoustic emissions in 8,836 newborns, diagnostic confirmation with auditory brainstem response, and treatment. Results: The coverage of the first two levels of otoacoustic emissions was 98.4 % and 99.5 %. The incidence of risk factors was 3.08 %. A total of 6.7 % of those studied in the first stage were referred to the second, and 0.7 % of those studied in the second stage were referred to testing of auditory brainstem responses. Of the patents referred to the second stage, 97.6 % attended, and of those referred to the third stage 87.1 % attended. The positive predictive value after the second session of otoemissions was 7.9 %, and the false positive rate was 3.3 %. Sensorineural and bilateral hearing loss was diagnosed in 11 children, and permanent unilateral hypoacousia was diagnosed in one child, representing an incidence of 1.38/1,000 newborns. Sixty percent were diagnosed before the age of 3 months and 100 % before the age of 7 months. Fifty percent began treatment before the age of 6 months and 90 % before the age of 1 year. Of three cochlear implants indicated, two were implanted at 11 and 13 months. The cost was 1.3 3 per child screened and 867 3 for each case diagnosed. Conclusions: All the objectives of the first and second stages of screening were achieved. The continuity index anticipated for the third stage (87.1 vs 95 %) and access to treatment at 6 months (50 % vs 100 %) were less satisfactory, although these results compare favorably with those of previously published studies. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|